• Manila Office:02-8221222
  • Kuala Lumpur Office:010-2066616
  • Indonesia Office ↓
  • +62 812-978-978-59 , +62 813-8183-7924
Request Information
What is ACTL™ cell targeted therapy?
ACTL™ cell targeted therapy, called AAV-DC-CTL TM tumor cell targeted therapy technology, also referred to as ACTL™technology, is the latest tumor biological treatment technology.
ACTL™ tumor targeted therapy uses the way to collect patients’ own cells and takes recombinant adeno-associated virus (rAAV) that carries anti-cancer gene as the carrier to transfuse in vitro prepared CTL cells into the patient through intravenous ways and ultimately kill tumor with these CTL cells.
Because the CTL cells obtained from ACTL™ own powerful targeted killing effect on tumor cells, clinical use of ACTL ™ technology on cancer treatment has obtained remarkable achievements. The survival rate has reached up to 85 % after treatment, thus ACTL™ technology has become the primary means of international clinical cancer treatment.
Why should we choose ACTL™ cell targeted therapy?
Effectively prevent the recurrence:
Clear postoperative residual cancer cells, prevent recurrence and prolong survival period of patients.
  • Safety:

    Adeno-associated virus (AAV) as the carrier of tumor antigen gene, has non-pathogenic feature or non-toxic side effects, and won’t damage human body's normal cells.

  • Targeting:

    The CTL cells obtained by ACTL™ technology have specific antigen (that is targeting) which can directly and powerfully kill tumor cells and neovascularization endothelial cells.

  • High efficiency:

    The efficiency for rAAV gene transfecting into DC cells reaches up to 95%. CTL cells can be largely applied to patients to kill tumor cells greatly.

  • Reversal of drug resistance:

    Reverse the resistance of tumor cells to drugs and improve radiotherapy and chemotherapy efficacy of patients.

  • Short treatment course:

    Single treatment lasts 12-14 days, and this is in line with the clinical needs of the majority of the patients.

  • Little trauma and less pain:

    Intravenous transfusion brings little trauma and less pain.

Outstanding contributions of ACTL™ cell targeted therapy
  • 2011 Nobel Prize

    Canadian scientist Ralph Steinman has been awarded with Nobel Prize in Medicine in 2011 for his findings on dendritic cells (DC cells) and their function on adaptive immune system.

  • Major Breakthrough Achievement Award of 2010 ASCO

    In early 2000s, Oncology Center of Medicine School of Stanford University combined recombinant adeno-associated virus (rAAV) with DC cells, and developed ACTL™technology. The results of the study were chosen as the most important breakthrough in the field of tumor biological treatment in 2010 by ASCO.

  • 5 international patents and FDA certification

    ACTL™ technology has won American patent, European patent and international patent (up to 5 patents protection), and been approved by FDA, NHI and other safety related institutes.

Why is ACTL™ cell targeted therapy so important?

ACTL™ cell targeted therapy has become one of the main tumor treatment techniques. Compared with traditional therapies and past tumor biological treatment, this therapy can greatly improve the survival rate.After receiving ACTL treatment, “the father of DC cells”-- Professor Steinman and Steve Jobs (CEO of Apple Co., Ltd), their survival time were respectively extended by four years and five years.

Due to clinical efficacy, the currently & clinically used cell immunotherapy of LAK cells, CIK cells or DC cells, tumor biological treatment is still regarded as a adjuvant treatment. However, ACTL™ tumor cell targeted therapy has definite and evaluable clinical efficacy, and its introduction has become a new breakthrough in tumor biological treatment.

(picture:the progress of cancer biotherapy)
How does ACTL™ cell targeted therapy work?
The application mechanism:

CTL cell is a T cell subset as well as a kind of specific T cell owning direct killing effect to certain viruses, tumor cells. Thus, CTL cells and natural killer cells have constituted the defensive line for antiviral & anti-tumor.

Treatment process of ACTL™ cell targeted therapy
Who can accept ACTL™ cell targeted therapy?
Applicable disease:

It can be applied to certain kind or several kinds of tumor-associated antigen positive malignant tumors, such as lung cancer, breast cancer, cervical cancer, colorectal cancer, prostate cancer, ovarian cancer, nasopharyngeal cancer, esophageal cancer, kidney cancer, bladder cancer, gastric cancer, pancreatic cancer, melanoma, lymphoma, multiple myeloma, etc.

Applicable stages:

Early cancer patients can adopt this therapy during or after surgery to improve the success rate of surgery;This therapy can be performed to cooperate with radiotherapy, chemotherapy, cryotherapy, radioactive particle implantation, interventional therapy, etc. to improve the therapeutic efficacy of advanced stage cancer patients;According to conditions of tumor, it can also be used alone to help patients improve immunity against cancer.

Efficacy and cases of ACTL™ cells targeted therapy
By observation, patients who received ACTLTM cells targeted therapy in our hospital have achieved satisfactory therapeutic effect. The vast majority of these patients who come to our hospital have already reached stage IV, and we believe that if the cancer patients were in earlier stages, the effect could be better.
·Clinical symptoms alleviation
After three months of ACTLTM cell targeted therapy, most patients’ clinical symptoms get alleviated. For example, for some prostate or breast cancer patients who have already occurred bone metastasis, bone pain gets relieved or disappears.
·Tumor marker decline in serum
After treatment, the vast majority of patients would experience different degrees of tumor marker decline in serum, and even return to normal.
·Metastatic lesions disappear
Most of the patients’ metastatic lesions would experience different degrees of reduction or even disappear, especially for lymph node metastatic lesion.
Prostate cancer
Advanced prostate cancer patients achieved good effect after ACTL™ cell targeted therapy.
Before treatment
7 months later, the tumor disappeared
Colorectal cancer
Advanced colorectal cancer patients achieved significant effect after ACTL™ cell targeted therapy.
Before treatment
the follow-up check after 10 months later
Breast cancer
After 4 months of ACTL™ cell targeted therapy for a breast cancer patient with spinal metastases, the metastatic lesion and spinal pain disappeared.
Before treatment
After 4 months of treatment
A non small cell lung adenocarcinoma
After ACTL™ cell targeted therapy, a non small cell lung adenocarcinoma patient’s tumor disappeared largely.
Before treatment
After treatment
ACTL™ in Modern Cancer Hospital Guangzhou
In Modern Cancer Hospital Guangzhou, our doctors and researchers have been contributing efforts to the research and clinical use of tumor biological treatment, and through discussion with worldwide cancer specialists, our hospital tumor biological treatment has been walking in the forefront of the international.
The application process of ACTL™ cell targeted therapy technology will involve our professional medical teams, including excellent ACTL™ cells targeted therapy experts, biological experts, immunological experts, tumors specialists specia-lized in cryotherapy, radioactive particle implantation, interventional therapy, etc. and other highly skilled nursing staff.
Due to differences of patients’ condition and physical status, comprehensive therapy shall be taken differently. We would try to improve the patient's treatment plan and reduce complications, so that patients shall have less pain but prolonged survival period with higher life quality.
(Figure: Director Zhang Dechun of biological immunotherapy participating in Tumor Biotherapy Conference)